<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-35027</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Jubilant Pharma</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">1) Creation of better quality jobs: JLS employs 6,277 people globally, including 1,018 dedicated to R&amp;D and in its pharmaceutical business; JPL employs more than 3,000 people, of which 50 percent are in India. The proposed investment will help maintain these jobs and create new ones, as JPL is able to launch new products, thanks to a stronger balance sheet.   2) Increased access to affordable quality healthcare: The Company&apos;&apos;s strong product pipeline and R&amp;D capability will enable better access to quality and affordable healthcare in the underserved markets, including India.   3) Demonstration effect: Through its financing, IFC will help a mid-sized company that has a solid business profile to strengthen its financial structure by lengthening the average maturity of its debt and minimizing its exposure to foreign exchange fluctuations. The proposed IFC financing will facilitate the corporate reorganization thereby enabling JPL to achieve sustainable growth.  4) Linkages:  The Company has a number of local linkages both in its pharmaceuticals and LSI business segments.  For example, on the LSI side, JLS has long-term contracts with local ethanol producers as well as purchases molasses from a number of sugar mills for its own distilleries. It also produces some ingredients that are used as agrochemicals with broad applications in agriculture.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">The proposed project (the Project) involves an IFC-led financing package that will help provide a counter cyclical and long-term financial support to Jubilant Pharma Limited, Singapore (JPL or the Company) and through JPL, to its parent company, Jubilant Life Sciences Limited, India (JLS or the Parent). JPL is a wholly owned subsidiary of JLS and with this financing, JLS plans to consolidate its pharmaceutical business under JPL. This financing package will help JLS to de-couple its pharmaceutical business from its life science ingredients (LSI) business and enhance shareholder value.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">JUBILANT PHARMA LIMITED</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-35027" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="3"></activity-status>
  <activity-date iso-date="2014-05-15" type="1"></activity-date>
  <activity-date iso-date="2014-05-23" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Due to the nature of this proposed investment, the corporate&apos;&apos;s contact and headquarters are being provided in lieu of project locations.  Name: Arun K Sharma Title: CFO Company: Jubilant Pharma Ltd.  Address: Plot 1A, Sector 16 A Noida  201301 Uttar Pradesh Tel: 0120 4361109 Mail to:  mailto:arun_sharma@jubl.com  Website:  http://www.jubl.com</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Name: Arun K Sharma Title: CFO Company: Jubilant Pharma Ltd.  Address: Plot 1A, Sector 16 A Noida  201301 Uttar Pradesh Tel: 0120 4361109 Mail to:  mailto:arun_sharma@jubl.com  Website:  http://www.jubl.com</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="IN" percentage="100">
   <narrative xml:lang="EN">India</narrative>
  </recipient-country>
  <location ref="IN-India">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">Under the Project, JLS will consolidate its pharmaceutical business under JPL, which primarily involves a transfer of JLSs Indian pharmaceutical assets to JPL.</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>22.0000000000 79.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector code="325" percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">G-FA - Pharmaceuticals and Medicine Manufacturing</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $110.00 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2014-05-15"></period-start>
   <period-end iso-date="2014-06-30"></period-end>
   <value currency="USD" value-date="2014-05-15">110000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2014-05-15"></transaction-date>
   <value currency="USD" value-date="2014-05-15">110000000</value>
   <receiver-org>
    <narrative xml:lang="EN">JUBILANT PHARMA LIMITED</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="411"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/35027/jubilant-pharma">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A01"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/35027/jubilant-pharma">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
